Supplementary Table 1 from Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma

Abstract

<p>Supplementary Table 1A (ST1A). Clinical features of CTCL (MF and SS) patients used in Figure 1B and Figure 4E (denoted with *). Stage 1B and IIB are MF samples and Stage III/IV are SS samples. Supplementary Table 1B (ST1B). Clinical features of SS patients whose CD4+ T cells were used in Figure 1C. Supplementary Table 1C (ST1C). Clinical features of SS patients whose CD4+ T cells were used in Figure 5B and Supplementary Figure 1D-F (denoted with #). Supplementary Table 1D (ST1D). Clinical features of SS patients whose CD4+ T cells were used in Figure 4D and 5A.</p>